I期临床试验中的双药剂量探索——快速入组设计的扩展
该文提出快速入组双药设计(REDD),用于I期临床试验双药联合的剂量探索,旨在以高概率为目标剂量组合给药。模拟显示REDD平均表现与贝叶斯最优区间(BOIN)设计和偏序持续再评估法(POCRM)相当,且在迟发型毒性评估中不显著影响最大耐受剂量(MTD)估计质量,同时节省入组时间。
要点
- REDD无需等待所有患者完成评估即可分配下一受试者。
- 模拟中REDD平均表现与BOIN和POCRM相当。
- 迟发型毒性下不等待随访不显著影响MTD估计质量,并节省入组时间。
核心结论
- REDD表现与BOIN和POCRM相似,易于理解、实施直接,且无需等待当前所有患者完成毒性随访即可入组患者。
研究设计与样本
- 提出快速入组双药设计(REDD),用于I期临床试验双药剂量探索。
- 通过模拟在多个情景下比较REDD与BOIN和POCRM的平均表现。
- 模拟评估REDD在迟发型毒性评估中的表现。
主要发现
- 模拟显示多个情景下REDD平均表现与BOIN和POCRM相当。
- 迟发型毒性模拟显示不等待最近队列完成随访即分配剂量组合,不显著损害MTD估计质量,并节省大量入组时间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dual-agent treatment has become more and more popular in clinical trials. We have developed an approach called rapid enrollment dual-agent design (REDD) for dose-finding in Phase I clinical trials. This approach aims to administer treatment to patients using a dose combination that is highly probable to be the target dose combination. Unlike other non-model-based designs, rapid enrollment designs (RED and REDD) do not require waiting for all patients to complete an assessment before the assignment of the next participant. Simulations showed that across several scenarios, the average performance of REDD is comparable to that of the Bayesian optimal interval (BOIN) design and the partial order continual reassessment method (POCRM). The simulation results of REDD for late-onset toxicity assessments demonstrated that assigning patients to a dose combination as they are being enrolled, without waiting for the most recent cohort of patients to complete their follow-up, does not significantly compromise the quality of the maximum tolerated dose (MTD) estimation. Instead, it saves a considerable amount of time in clinical trial enrollment. User-friendly online applications have also been created to further facilitate the adoption of rapid enrollment designs in Phase I trials. In summary, being similar to BOIN and POCRM in performance, REDD is an approach that is easily comprehensible, straightforward to implement and offers an advantage of enrolling patients without having to wait for all current patients to complete their follow-ups for toxicity.
引用
- Wang Y. Dual-agent dose-finding in Phase I clinical trial-An extension of rapid enrollment design. Stat Med. 2024. PMID: 39075332. doi:10.1002/sim.10185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。